Navigation Links
AlphaRx CEO Accumulates More Company Shares
Date:1/9/2008

MARKHAM, ON, Jan. 9 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News) stated on Tuesday that CEO Michael Lee purchased 720,000 shares of AlphaRx Inc Common Stock in the open market, bringing the total number of shares purchased to 2,219,700 within the last 60 days, reflecting his continued confidence in the Company's future.

Mr. Michael Lee reported buying a total of 720,000 AlphaRx shares for an average price of $0.24 each, increasing his holdings to about 15,609,814 shares or 17.06% of the company, according to a filing with the Securities and Exchange Commission.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
2. AlphaRx Announces Debt Conversion
3. AlphaRx To Present at 47th Annual ICAAC
4. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
5. New Colonial Life Brand Clarifies Companys Strengths
6. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
7. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
8. KV Pharmaceutical Company Announces NYSE Listing Extension
9. Nevada company, ORNL develop potential lifesaver
10. Life Denied: California Nurses, Family of Sick Teen March on Health Insurance Company Thursday
11. Medicare Fraud Strike Force Cases Result in Long Prison Terms for Five Health Care Company Owners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: